The global liquid biopsy market is forecast to reach $2,047.9 million by 2022 from $715.7 million in 2017 at a CAGR of 23.4% during (2017-2022) driven by the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.
Browse report at www.reportsnreports.com/contacts/r….aspx?name=631133 .
North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.
1 Liquid Biopsy Market: Overview
2 Global Market, By Clinical Application (2017)
3 Global Market: Geographic Growth Opportunities
4 Global Market: Geographic Mix
5 Global Market: Established vs Emerging Markets
The major market players in the liquid biopsy market are QIAGEN N.V.
(Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc.
(US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc.
(US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc.
(US), and MDxHealth SA (US).
Access report at www.reportsnreports.com/purchase.aspx?name=631133 .
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period.
This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.
The extracellular vesicles to register the highest CAGR of liquid biopsy market during the forecast period. Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers.
The extracellular vesicles segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring.
Make an Inquiry at www.reportsnreports.com/contacts/i….aspx?name=631133 .
Break of primary participants was as mentioned below:
- By Company Type: Tier 1 - 15%, Tier 2 - 45%, and Tier 3 - 40%
- By Designation: C-level - 27%, Director Level - 33%, Others - 40%
- By Region: North America - 25%, Europe - 45%, Asia-Pacific - 15%, RoW - 15%
The report analyzes the liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by product, circulating biomarker, clinical application, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.